Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2025)

Ultragenyx Pharmaceutical has reported Revenue over the past 10 years, most recently at $207.3 million for Q4 2025.

  • Quarterly Revenue rose 25.89% to $207.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $673.0 million through Dec 2025, up 20.18% year-over-year, with the annual reading at $673.0 million for FY2025, 20.18% up from the prior year.
  • Revenue was $207.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $159.9 million in the prior quarter.
  • Over five years, Revenue peaked at $207.3 million in Q4 2025 and troughed at $79.9 million in Q1 2022.
  • The 5-year median for Revenue is $105.8 million (2022), against an average of $119.1 million.
  • Year-over-year, Revenue surged 173.75% in 2021 and then decreased 19.58% in 2022.
  • A 5-year view of Revenue shows it stood at $83.4 million in 2021, then grew by 23.93% to $103.3 million in 2022, then increased by 23.02% to $127.1 million in 2023, then grew by 29.5% to $164.6 million in 2024, then increased by 25.89% to $207.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Revenue are $207.3 million (Q4 2025), $159.9 million (Q3 2025), and $166.5 million (Q2 2025).